The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized, double-blind phase 3 trial of the fixed-dose combination fosrolapitant/palonosetron (HR20013) plus dexamethasone for prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
 
Li Zhang
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - Akeso Biopharma; AstraZeneca; CHINA SHIYAO PHARMA; HenRui; Roche; Sichuan Biokin Pharmaceutical
Research Funding - Akeso Biopharma (Inst); AstraZeneca (Inst); BMS (Inst); Chia Tai Tianqing Pharmaceutical Group (Inst); QiLu Pharmaceutical (Inst); Sichuan Biokin Pharmaceutical, (Inst); Sichuan Kelun-Biotech Biopharmaceutical (Inst)
 
Yu-hong Li
No Relationships to Disclose
 
De-Shen Wang
No Relationships to Disclose
 
Wei Deng
No Relationships to Disclose
 
SongNan Zhang
No Relationships to Disclose
 
Feng Wang
No Relationships to Disclose
 
Jianfei Fu
No Relationships to Disclose
 
Mao Zhang
No Relationships to Disclose
 
Zhaofeng Zhu
No Relationships to Disclose
 
Shengjie Yin
No Relationships to Disclose
 
Liangwei Yin
No Relationships to Disclose
 
Xiaojie Zhuang
No Relationships to Disclose
 
Wanzhi Wang
No Relationships to Disclose
 
Chunping Lin
No Relationships to Disclose
 
Xiao-bo Du
No Relationships to Disclose
 
Gengsheng Yu
No Relationships to Disclose
 
Li Liu
No Relationships to Disclose
 
Yunhui Huang
No Relationships to Disclose
 
Shuang Leng
No Relationships to Disclose
 
Junying Xu
No Relationships to Disclose